Opinion
Events since 11 September have caused pharmaceutical companies to question their intellectual property (IP) rights and the power of governments to override those rights in times of national emergency. On 24 October, the US Department of Health & Human Services and the Bayer Corporation announced their agreement for a significant new federal purchase of the […]